New Street Research - Vodafone Group (VOD LN) Revealing the spectrum sale details from Vod-Three to O2 (potentially!)

Report

New Street Research

James Ratzer

EUR 9580.00 For Business Accounts Only

Revealing the spectrum sale details from Vod-Three to O2 (potentially!)

The merger of Vodafone-Three is the biggest change in the UK wireless market in many years. But potentially the second biggest change is the size of the spectrum sale from Vod-Three to O2. This has the potential to shape competitive dynamics for years to come and we believe we have unearthed new details of the spectrum transfer to steer people in the right direction for a likely outcome.

17/01/2025 1 EN

Underlying

Vodafone Group

See profile

Provider

New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

Pan European Telecom Services and Cable
US Telecoms, Cable, Satellite and Towers
Global Emerging Market Telecoms
Japan Telecoms
Asian Internet
Pan European Healthcare
Global healthcare thematic research

We provide debt research on:

Pan European Telecom Services and Cable

See profile

Analysts

James Ratzer

Other Reports on these Companies

New Street Research

German mobile pricing deteriorating Assessing the most recent moves

Over the past few months, we have been writing on the increased signs of competitive intensity in the German mobile market. We are only nine days into the New Year and sadly there are signs of this further heating up with new moves by DT and 1&1. In this report, we review those moves in more detail and consider the potential impact on all the companies involved (DT, Vodafone, Telefonica and 1&1).

EUR 9580.00

January 9, 2025 January 9, 2025 1 EN

New Street Research

European Telecoms: The Year Ahead 2025 Ongoing regulatory support allowing for superior FCF growth

2024 saw the best outperformance for the telecoms sector since 2013 (and the third best since 2000) and ironically this came in a year with one of the lowest announced M&A volumes. We believe this is a testament to improved perception of the underlying fundamentals.

EUR 9580.00

December 18, 2024 December 18, 2024 1 EN

NSR Policy: OMB Orders Spending Pause: BEAD and USF Impact

Last week, we published two notes on the initial set of Trump Executive Orders (EOs) and their impact on the BEAD program. In the first, we noted that the program had escaped any impact, despite a vaguely worded order that some interpreted pausing payments for all infrastructure related expenditures. The White House subsequently confirmed our interpretation. But we warned that there were many more EOs to come and it was likely that there would be some Administration action affecting the program. That may have arrived late yesterday with an Office of Management and Budget (OMB) memo pausing fed...

EUR 9580.00

13h / 22m 13h / 22m 1 EN

Soomit Datta

Soomit Datta

KSPI (BUY, TP: $130, +40%)) - Tough transition year, estimates/target lowered / CALL REPLAY

We held a call with Kaspi last week. While FY 24 (and Q4) earnings guide looks set to be delivered when reported (24 Feb), 2025 will be a tough transition year for Kaspi, with rate rises in Kazakhstan toward the end of last year dampening profitability expectations.

EUR 9580.00

21h / 21m 21h / 21m 1 EN

Dominic Rose ... (+2)

Dominic Rose
Naresh Chouhan

Novo Nordisk - Amycretin Data to Drive Re-Rating (BUY, TP DKK 880 [800])

After the disappointing CagriSema data, Novo shares de-rated in large part due to growing concerns about the sema patent expiry & ability to sustain growth beyond 2031. Whilst we did not share these concerns & are not worried about declines post the sema LOE for a multitude of reasons, we are aware that we are in the minority. However, with the amycretin data showing best-in class weight loss, Novo’s ability to compete with LLY, switch patients from Wegovy & deliver growth beyond 2031 is now much more likely. In our obesity model we now have $36bn 2030 sales for the Novo franchise, amycretin p...

EUR 4790.00

22h / 53m 22h / 53m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Revealing the spectrum sale details from Vod-Three to O2 (potentially!)

German mobile pricing deteriorating Assessing the most recent moves

European Telecoms: The Year Ahead 2025 Ongoing regulatory support allowing for superior FCF growth

NSR Policy: OMB Orders Spending Pause: BEAD and USF Impact

KSPI (BUY, TP: $130, +40%)) - Tough transition year, estimates/target lowered / CALL REPLAY

Novo Nordisk - Amycretin Data to Drive Re-Rating (BUY, TP DKK 880 [800])

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe